Durvalumab vs Pembrolizumab

## Durvalumab vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Pembrolizumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Pembrolizumab — 26 days.

## Chemical Properties

**Type**: Durvalumab — Antibody; Pembrolizumab — Antibody.